Karyopharm announces preliminary unaudited fourth quarter and full year 2022 revenue and outlines 2023 objectives

– preliminary unaudited full year 2022 total revenue and u.s. xpovio ®  (selinexor) net product revenue expected to be approximately $157.7 million and $120.4 million, respectively, meeting company's guidance – – initiated pivotal phase 3 study evaluating selinexor as a maintenance therapy in women with advanced or recurrent tp53 wild-type endometrial cancer; encouraging updated exploratory subgroup analysis in patients with tp53 wild-type endometrial cancer continues to support study rationale; partnership with foundation medicine to develop tp53 companion diagnostic – – planning to initiate pivotal phase 3 study in front-line myelofibrosis in 1h 2023; report updated results from the phase 1 study of selinexor in combination with ruxolitinib in patients with treatment-naÏve mf in 1h 2023 – – anticipate multiple data catalysts and progress across multiple myeloma, myelofibrosis, endometrial cancer and myelodysplastic neoplasms in 2023 –  – extended cash runway to late 2025 – newton, mass. , jan. 9, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2022 total revenue and u.s. xpovio net product revenue estimates and outlined its 2022 achievements and 2023 objectives.
KPTI Ratings Summary
KPTI Quant Ranking